GAMMA Investing LLC boosted its stake in National Research Corporation (NASDAQ:NRC - Free Report) by 45,978.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,206 shares of the company's stock after buying an additional 15,173 shares during the period. GAMMA Investing LLC owned 0.07% of National Research worth $195,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of NRC. Geode Capital Management LLC lifted its stake in shares of National Research by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 435,707 shares of the company's stock worth $7,687,000 after acquiring an additional 14,974 shares during the period. Renaissance Technologies LLC raised its holdings in National Research by 6.6% during the fourth quarter. Renaissance Technologies LLC now owns 404,886 shares of the company's stock worth $7,142,000 after purchasing an additional 25,002 shares in the last quarter. Northern Trust Corp lifted its position in National Research by 2.7% in the fourth quarter. Northern Trust Corp now owns 293,755 shares of the company's stock worth $5,182,000 after purchasing an additional 7,853 shares during the period. Bank of New York Mellon Corp lifted its position in National Research by 88.5% in the fourth quarter. Bank of New York Mellon Corp now owns 217,212 shares of the company's stock worth $3,832,000 after purchasing an additional 101,957 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in National Research by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 124,711 shares of the company's stock valued at $2,200,000 after purchasing an additional 970 shares in the last quarter. Institutional investors and hedge funds own 47.26% of the company's stock.
National Research Stock Down 1.7%
Shares of NRC stock opened at $16.55 on Monday. National Research Corporation has a 1 year low of $9.76 and a 1 year high of $27.07. The company has a debt-to-equity ratio of 1.98, a quick ratio of 0.54 and a current ratio of 0.54. The business's fifty day moving average is $13.40 and its 200-day moving average is $15.10. The stock has a market cap of $377.09 million, a PE ratio of 16.07 and a beta of 0.38.
National Research (NASDAQ:NRC - Get Free Report) last announced its earnings results on Monday, April 28th. The company reported $0.25 earnings per share for the quarter. The business had revenue of $33.55 million during the quarter. National Research had a return on equity of 71.33% and a net margin of 17.14%.
National Research Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $0.48 annualized dividend and a dividend yield of 2.90%. National Research's dividend payout ratio (DPR) is 46.60%.
Insider Activity
In related news, major shareholder Patrick E. Beans purchased 2,500 shares of the company's stock in a transaction on Monday, May 12th. The shares were bought at an average price of $13.59 per share, with a total value of $33,975.00. Following the completion of the acquisition, the insider now owns 35,003 shares of the company's stock, valued at approximately $475,690.77. This represents a 7.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 8.10% of the company's stock.
National Research Company Profile
(
Free Report)
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider National Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Research wasn't on the list.
While National Research currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
